<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37296644</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Current State and Future Directions in the Therapy of ALS.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12111523</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder affecting upper and lower motor neurons, with death resulting mainly from respiratory failure three to five years after symptom onset. As the exact underlying causative pathological pathway is unclear and potentially diverse, finding a suitable therapy to slow down or possibly stop disease progression remains challenging. Varying by country Riluzole, Edaravone, and Sodium phenylbutyrate/Taurursodiol are the only drugs currently approved in ALS treatment for their moderate effect on disease progression. Even though curative treatment options, able to prevent or stop disease progression, are still unknown, recent breakthroughs, especially in the field of targeting genetic disease forms, raise hope for improved care and therapy for ALS patients. In this review, we aim to summarize the current state of ALS therapy, including medication as well as supportive therapy, and discuss the ongoing developments and prospects in the field. Furthermore, we highlight the rationale behind the intense research on biomarkers and genetic testing as a feasible way to improve the classification of ALS patients towards personalized medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tzeplaeff</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0003-7643-3232</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Rechts der Isar Hospital, Technical University of Munich, 81675 M&#xfc;nchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilfling</LastName><ForeName>Sibylle</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, 93053 Regensburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetics Regensburg, 93059 Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requardt</LastName><ForeName>Maria Viktoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Formerly: Department of Neurology with Institute of Translational Neurology, M&#xfc;nster University Hospital (UKM), 48149 M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herdick</LastName><ForeName>Meret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Precision Neurology, University of L&#xfc;beck, 23562 Luebeck, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BMBF 01ED2204A</GrantID><Agency>The EU Joint Programme - Neurodegenerative Disease Research (JPND)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">MND</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">medication</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword><Keyword MajorTopicYN="N">supportive therapy</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37296644</ArticleId><ArticleId IdType="pmc">PMC10252394</ArticleId><ArticleId IdType="doi">10.3390/cells12111523</ArticleId><ArticleId IdType="pii">cells12111523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoulopoulou E., Fini N., Vinceti M., Monelli M., Vacondio P., Bianconi G., Sola P., Nichelli P., Mandrioli J. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: A population based study in Modena, Italy. Amyotroph. Lateral Scler. Front. Degener. 2013;14:338&#x2013;345. doi: 10.3109/21678421.2013.763281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.763281</ArticleId><ArticleId IdType="pubmed">23373475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M., Smith A. Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener. Neurol. Neuromuscul. Dis. 2017;7:61&#x2013;70. doi: 10.2147/DNND.S135748.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S135748</ArticleId><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R.J., Shan N., Reiser H.J., Marshall F., Shaw P.J. Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 2023;22:185&#x2013;212. doi: 10.1038/s41573-022-00612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pmc">PMC9768794</ArticleId><ArticleId IdType="pubmed">36543887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Halliday G.M., Kril J.J., G&#xf6;tz J., Hodges J.R., Kiernan M.C. FTD and ALS--translating mouse studies into clinical trials. Nat. Rev. Neurol. 2015;11:360&#x2013;366. doi: 10.1038/nrneurol.2015.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.65</ArticleId><ArticleId IdType="pubmed">25939274</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Bedlack R., Andrews J.A., Berry J.D., Bowser R., Brown R., Glass J.D., Maragakis N.J., Miller T.M., Rothstein J.D., et al. Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers: A Review. JAMA Neurol. 2022;79:1312&#x2013;1318. doi: 10.1001/jamaneurol.2022.3282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.3282</ArticleId><ArticleId IdType="pubmed">36251310</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S.A., Fang T., De Marchi F., Neel D., Van Weehaeghe D., Berry J.D., Paganoni S. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs. 2022;82:1367&#x2013;1388. doi: 10.1007/s40265-022-01769-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01769-1</ArticleId><ArticleId IdType="pubmed">36121612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Hombrados L., Molina-Torres G., Gal&#xe1;n-Mercant A., S&#xe1;nchez-Guerrero E., Gonz&#xe1;lez-S&#xe1;nchez M., Ruiz-Mu&#xf1;oz M. Systematic Review of Therapeutic Physical Exercise in Patients with Amyotrophic Lateral Sclerosis over Time. Int. J. Environ. Res. Public Health. 2021;18:1074. doi: 10.3390/ijerph18031074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031074</ArticleId><ArticleId IdType="pmc">PMC7908444</ArticleId><ArticleId IdType="pubmed">33530383</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang C.-S., Weng H.-H., Wang L.-F., Tsai C.-H., Chang H.-T. An eye-tracking assistive device improves the quality of life for ALS patients and reduces the caregivers&#x2019; burden. J. Mot. Behav. 2014;46:233&#x2013;238. doi: 10.1080/00222895.2014.891970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00222895.2014.891970</ArticleId><ArticleId IdType="pubmed">24731126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Silva J.P., Santiago J&#xfa;nior J.B., Dos Santos E.L., de Carvalho F.O., de Fran&#xe7;a Costa I.M.P., de Mendon&#xe7;a D.M.F. Quality of life and functional independence in amyotrophic lateral sclerosis: A systematic review. Neurosci. Biobehav. Rev. 2020;111:1&#x2013;11. doi: 10.1016/j.neubiorev.2019.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.12.032</ArticleId><ArticleId IdType="pubmed">31917162</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. Andersen P.M., Abrahams S., Borasio G.D., de Carvalho M., Chio A., Van Damme P., Hardiman O., Kollewe K., Morrison K.E., et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur. J. Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Dorst J., Dreyhaupt J., Weishaupt J.H., Kassubek J., Weiland U., Meyer T., Petri S., Hermann A., Emmer A., et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2020;87:206&#x2013;216. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke S.C., Tomlinson M., Williams T.L., Bullock R.E., Shaw P.J., Gibson G.J. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial. Lancet Neurol. 2006;5:140&#x2013;147. doi: 10.1016/S1474-4422(05)70326-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.A., Lally C., Kupelian V., Flanders W.D. Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants. Neuroepidemiology. 2021;55:342&#x2013;353. doi: 10.1159/000516752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516752</ArticleId><ArticleId IdType="pubmed">34247168</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E.O., Malek A.M., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A., Peter R.S., Erhardt S., Lul&#xe9; D., Rothenbacher D., Ludolph A.C., Nagel G., ALS Registry Study Group Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J. Neurol. 2017;264:749&#x2013;757. doi: 10.1007/s00415-017-8413-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8413-3</ArticleId><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Shen D., Yang X., Cui B., Tai H., Wang Z., Liu S., Zhang K., Liu M., Cui L. Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis. J. Clin. Neurosci. 2019;69:74&#x2013;80. doi: 10.1016/j.jocn.2019.08.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2019.08.030</ArticleId><ArticleId IdType="pubmed">31447367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.M., Fagegaltier D., Phatnani H., Harms M.B. Genetics of Amyotrophic Lateral Sclerosis. Curr. Genet. Med. Rep. 2020;8:121&#x2013;131. doi: 10.1007/s40142-020-00194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40142-020-00194-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Albo F., Pieri M., Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res. 2004;78:200&#x2013;207. doi: 10.1002/jnr.20244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20244</ArticleId><ArticleId IdType="pubmed">15378511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretschmer B.D., Kratzer U., Schmidt W.J. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn-Schmiedeberg&#x2019;s Arch. Pharm. 1998;358:181&#x2013;190. doi: 10.1007/PL00005241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00005241</ArticleId><ArticleId IdType="pubmed">9750003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli E., Funicello M., Rauen T., Gobbi M., Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharm. 2008;578:171&#x2013;176. doi: 10.1016/j.ejphar.2007.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2007.10.023</ArticleId><ArticleId IdType="pubmed">18036519</ArticleId></ArticleIdList></Reference><Reference><Citation>Theile J.W., Cummins T.R. Inhibition of Nav&#x3b2;4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide. Mol. Pharm. 2011;80:724&#x2013;734. doi: 10.1124/mol.111.072751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.111.072751</ArticleId><ArticleId IdType="pmc">PMC3187525</ArticleId><ArticleId IdType="pubmed">21788423</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Benz A., Fu T., Wang M., Covey D.F., Zorumski C.F., Mennerick S. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002;42:199&#x2013;209. doi: 10.1016/S0028-3908(01)00175-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(01)00175-7</ArticleId><ArticleId IdType="pubmed">11804616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Powe L., Durrleman S., Delumeau J.C., Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242&#x2013;S250. doi: 10.1212/WNL.47.6_Suppl_4.242S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.242S</ArticleId><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Jackson C.E., Heiman-Patterson T.D., Bettica P., Brooks B.R., Pioro E.P. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Bettica P., Cazzaniga S. Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Clin. Ther. 2019;41:2490&#x2013;2499. doi: 10.1016/j.clinthera.2019.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2019.09.016</ArticleId><ArticleId IdType="pubmed">31635890</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer A.M., Smith A. Riluzole 5 mg/mL oral suspension: For optimized drug delivery in amyotrophic lateral sclerosis. Drug Des. Dev. Ther. 2017;11:59&#x2013;64. doi: 10.2147/DDDT.S123776.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S123776</ArticleId><ArticleId IdType="pmc">PMC5191840</ArticleId><ArticleId IdType="pubmed">28053507</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi I., Lovegren M., Wirtz V., Larouche R., Tanguay M., Anderson M.S., Hartmann S., Coric V., Berman R.M. A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV-0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers. Clin. Pharm. Drug Dev. 2020;9:476&#x2013;485. doi: 10.1002/cpdd.747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.747</ArticleId><ArticleId IdType="pubmed">31610101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wymer J., Apple S., Harrison A., Hill B.A. Pharmacokinetics, Bioavailability, and Swallowing Safety with Riluzole Oral Film. Clin. Pharm. Drug Dev. 2023;12:57&#x2013;64. doi: 10.1002/cpdd.1168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.1168</ArticleId><ArticleId IdType="pmc">PMC10087659</ArticleId><ArticleId IdType="pubmed">36168148</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Tanaka M., Yuki S., Hirai M., Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J. Clin. Biochem. Nutr. 2018;62:20&#x2013;38. doi: 10.3164/jcbn.17-62.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId><ArticleId IdType="pmc">PMC5773834</ArticleId><ArticleId IdType="pubmed">29371752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Iwasaki Y., Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 2015;354:70&#x2013;74. doi: 10.1016/j.jns.2015.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.052</ArticleId><ArticleId IdType="pubmed">25982504</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J. Pharm. Exp. 1994;268:1597&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">8138971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T., Yuki S., Watanabe T., Mitsuka M., Saito K.I., Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 1997;762:240&#x2013;242. doi: 10.1016/S0006-8993(97)00490-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00490-3</ArticleId><ArticleId IdType="pubmed">9262182</ArticleId></ArticleIdList></Reference><Reference><Citation>The Writing Group. Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>EDARAVONE (MCI-186) ALS 16 STUDY GROUP A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:11&#x2013;19. doi: 10.1080/21678421.2017.1363780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1363780</ArticleId><ArticleId IdType="pubmed">28872917</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S., Maier A., Steinbach R., Grosskreutz J., Koch J.C., Sarikidi A., Petri S., G&#xfc;nther R., Wolf J., Hermann A., et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients with Amyotrophic Lateral Sclerosis. JAMA Neurol. 2022;79:121&#x2013;130. doi: 10.1001/jamaneurol.2021.4893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Moglia C., Lizio A., Caponnetto C., Dubbioso R., Giannini F., Mat&#xe0; S., Mazzini L., Sabatelli M., Siciliano G., et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J. Neurol. 2020;267:3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz M.P. Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis. Pharm. Ther. 2018;43:25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737249</ArticleId><ArticleId IdType="pubmed">29290672</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph. Lateral Scler. 2006;7:241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;a-Quintana L., Llarena M., Reyes-Su&#xe1;rez D., Ald&#xe1;miz-Echevarria L. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: Patient perspectives. Patient Prefer. Adherence. 2017;11:1489&#x2013;1496. doi: 10.2147/PPA.S136754.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S136754</ArticleId><ArticleId IdType="pmc">PMC5593420</ArticleId><ArticleId IdType="pubmed">28919721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 1999;159:2647&#x2013;2658. doi: 10.1001/archinte.159.22.2647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.159.22.2647</ArticleId><ArticleId IdType="pubmed">10597755</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Signore S.J., Amante D.J., Kim J., Stack E.C., Goodrich S., Cormier K., Smith K., Cudkowicz M.E., Ferrante R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 2009;10:85&#x2013;94. doi: 10.1080/17482960802226148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802226148</ArticleId><ArticleId IdType="pubmed">18618304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005;93:1087&#x2013;1098. doi: 10.1111/j.1471-4159.2005.03077.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03077.x</ArticleId><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M. Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives. Cells. 2019;8:1471. doi: 10.3390/cells8121471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121471</ArticleId><ArticleId IdType="pmc">PMC6952947</ArticleId><ArticleId IdType="pubmed">31757001</ArticleId></ArticleIdList></Reference><Reference><Citation>Dion&#xed;sio P.A., Amaral J.D., Ribeiro M.F., Lo A.C., D&#x2019;Hooge R., Rodrigues C.M.P. Amyloid-&#x3b2; pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol. Aging. 2015;36:228&#x2013;240. doi: 10.1016/j.neurobiolaging.2014.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.08.034</ArticleId><ArticleId IdType="pubmed">25443293</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Knowlton N., Macklin E.A., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Knowlton N., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: Long-term results from the CENTAUR trial. J. Neurol. Neurosurg. Psychiatry. 2022;93:871&#x2013;875. doi: 10.1136/jnnp-2022-329024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId><ArticleId IdType="pmc">PMC9304116</ArticleId><ArticleId IdType="pubmed">35577511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Jozsa F., Al-Chalabi A. Nonmotor Symptoms in Amyotrophic Lateral Sclerosis: A Systematic Review. Int. Rev. Neurobiol. 2017;134:1409&#x2013;1441. doi: 10.1016/bs.irn.2017.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2017.04.009</ArticleId><ArticleId IdType="pubmed">28805578</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R., Pioro E., Myers K., Sirdofsky M., Goslin K., Meekins G., Yu H., Wymer J., Cudkowicz M., Macklin E.A., et al. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics. 2017;14:762&#x2013;772. doi: 10.1007/s13311-016-0508-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Bottacchi E., Buffa C., Mutani R., Mora G., The PARALS Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J. Neurol. Neurosurg. Psychiatry. 2006;77:948&#x2013;950. doi: 10.1136/jnnp.2005.083402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083402</ArticleId><ArticleId IdType="pmc">PMC2077622</ArticleId><ArticleId IdType="pubmed">16614011</ArticleId></ArticleIdList></Reference><Reference><Citation>Paipa A.J., Povedano M., Barcelo A., Dom&#xed;nguez R., Saez M., Turon J., Prats E., Farrero E., Virgili N., Mart&#xed;nez J.A., et al. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in Spain: Association with noninvasive mechanical ventilation. J. Multidiscip. Healthc. 2019;12:465&#x2013;470. doi: 10.2147/JMDH.S205313.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S205313</ArticleId><ArticleId IdType="pmc">PMC6590410</ArticleId><ArticleId IdType="pubmed">31354285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A., Foley G., Henderson R.D., James N., Aoun S.M. Amyotrophic lateral sclerosis: Improving care with a multidisciplinary approach. J. Multidiscip. Healthc. 2017;10:205&#x2013;215. doi: 10.2147/JMDH.S134992.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JMDH.S134992</ArticleId><ArticleId IdType="pmc">PMC5446964</ArticleId><ArticleId IdType="pubmed">28579792</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert S.M., Murphy P.L., Del Bene M.L., Rowland L.P. Prospective study of palliative care in ALS: Choice, timing, outcomes. J. Neurol. Sci. 1999;169:108&#x2013;113. doi: 10.1016/S0022-510X(99)00227-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00227-0</ArticleId><ArticleId IdType="pubmed">10540017</ArticleId></ArticleIdList></Reference><Reference><Citation>Munroe C.A., Sirdofsky M.D., Kuru T., Anderson E.D. End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir. Care. 2007;52:996&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">17650354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould R.L., Coulson M.C., Brown R.G., Goldstein L.H., Al-Chalabi A., Howard R.J. Psychotherapy and pharmacotherapy interventions to reduce distress or improve well-being in people with amyotrophic lateral sclerosis: A systematic review. Amyotroph. Lateral Scler. Front. Degener. 2015;16:293&#x2013;302. doi: 10.3109/21678421.2015.1062515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062515</ArticleId><ArticleId IdType="pubmed">26174444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulton J.J., Newins A.R., Porter L.S., Ramos K. Psychotherapy Targeting Depression and Anxiety for Use in Palliative Care: A Meta-Analysis. J. Palliat. Med. 2018;21:1024&#x2013;1037. doi: 10.1089/jpm.2017.0576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2017.0576</ArticleId><ArticleId IdType="pubmed">29676960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Sansone V.A., Cellotto N.M., Maestri E., Bettinelli M., Gatti V., Melazzini M.G., Meola G., Corbo M. Strictly monitored exercise programs reduce motor deterioration in ALS: Preliminary results of a randomized controlled trial. J. Neurol. 2016;263:52&#x2013;60. doi: 10.1007/s00415-015-7924-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7924-z</ArticleId><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Clawson L.L., Cudkowicz M., Krivickas L., Brooks B.R., Sanjak M., Allred P., Atassi N., Swartz A., Steinhorn G., Uchil A., et al. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2018;19:250&#x2013;258. doi: 10.1080/21678421.2017.1404108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1404108</ArticleId><ArticleId IdType="pubmed">29191052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Xu Y., Xuan R., Huang J., Istv&#xe1;n B., Fekete G., Gu Y. Mixed Comparison of Different Exercise Interventions for Function, Respiratory, Fatigue, and Quality of Life in Adults with Amyotrophic Lateral Sclerosis: Systematic Review and Network Meta-Analysis. Front. Aging Neurosci. 2022;14:919059. doi: 10.3389/fnagi.2022.919059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.919059</ArticleId><ArticleId IdType="pmc">PMC9309467</ArticleId><ArticleId IdType="pubmed">35898325</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A., Eicher C., Kiselev J., Klebbe R., Greu&#xe8;l M., Kettemann D., Gaudlitz M., Walter B., Oleimeulen U., M&#xfc;nch C., et al. Acceptance of Enhanced Robotic Assistance Systems in People with Amyotrophic Lateral Sclerosis-Associated Motor Impairment: Observational Online Study. JMIR Rehabil. Assist. Technol. 2021;8:e18972. doi: 10.2196/18972.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/18972</ArticleId><ArticleId IdType="pmc">PMC8691409</ArticleId><ArticleId IdType="pubmed">34874891</ArticleId></ArticleIdList></Reference><Reference><Citation>Driessen M.J., Dekker J., Lankhorst G., van der Zee J. Occupational therapy for patients with chronic diseases: CVA, rheumatoid arthritis and progressive diseases of the central nervous system. Disabil. Rehabil. 1997;19:198&#x2013;204. doi: 10.3109/09638289709166527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09638289709166527</ArticleId><ArticleId IdType="pubmed">9184785</ArticleId></ArticleIdList></Reference><Reference><Citation>Janiszewski D.W., Caroscio J.T., Wisham L.H. Amyotrophic lateral sclerosis: A comprehensive rehabilitation approach. Arch. Phys. Med. Rehabil. 1983;64:304&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">6860106</ArticleId></ArticleIdList></Reference><Reference><Citation>Braile L.E. Support for the drooping head. Am. J. Occup. 1981;35:661&#x2013;662. doi: 10.5014/ajot.35.10.661.</Citation><ArticleIdList><ArticleId IdType="doi">10.5014/ajot.35.10.661</ArticleId><ArticleId IdType="pubmed">7294137</ArticleId></ArticleIdList></Reference><Reference><Citation>Raglio A., Giovanazzi E., Pain D., Baiardi P., Imbriani C., Imbriani M., Mora G. Active music therapy approach in amyotrophic lateral sclerosis: A randomized-controlled trial. Int. J. Rehabil. Res. 2016;39:365&#x2013;367. doi: 10.1097/MRR.0000000000000187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MRR.0000000000000187</ArticleId><ArticleId IdType="pubmed">27437724</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson C.R. Aquatic therapy for an ALS patient. Am. J. Occup. 1988;42:115&#x2013;120. doi: 10.5014/ajot.42.2.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.5014/ajot.42.2.115</ArticleId><ArticleId IdType="pubmed">3348337</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebbe R., Scherzinger S., Eicher C. Assistive Robots for Patients with Amyotrophic Lateral Sclerosis: Exploratory Task-Based Evaluation Study with an Early-Stage Demonstrator. JMIR Rehabil. Assist. Technol. 2022;9:e35304. doi: 10.2196/35304.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/35304</ArticleId><ArticleId IdType="pmc">PMC9449829</ArticleId><ArticleId IdType="pubmed">35998031</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheu V., Frappier J., Archambault P.S., Routhier F. Evaluation of the JACO robotic arm: Clinico-economic study for powered wheelchair users with upper-extremity disabilities. IEEE Int. Conf. Rehabil. Robot. 2011;2011:5975397. doi: 10.1109/ICORR.2011.5975397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ICORR.2011.5975397</ArticleId><ArticleId IdType="pubmed">22275600</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti T., O&#x2019;Neill C., Gerez L., Cole T., Mendelowitz S., Nuckols K., Hohimer C., Lin D., Paganoni S., Walsh C. Restoring arm function with a soft robotic wearable for individuals with amyotrophic lateral sclerosis. Sci. Transl. Med. 2023;15:eadd1504. doi: 10.1126/scitranslmed.add1504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.add1504</ArticleId><ArticleId IdType="pubmed">36724237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan K., Koyama S., Sakurai H., Teranishi T., Kanada Y., Tanabe S. Wearable robotic exoskeleton for gait reconstruction in patients with spinal cord injury: A literature review. J. Orthop. Transl. 2021;28:55&#x2013;64. doi: 10.1016/j.jot.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jot.2021.01.001</ArticleId><ArticleId IdType="pmc">PMC7930505</ArticleId><ArticleId IdType="pubmed">33717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Olar M.-L., Leba M., Risteiu M. Exoskeleton&#x2014;Wearable devices. Literature review. MATEC Web Conf. 2021;342:05005. doi: 10.1051/matecconf/202134205005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/matecconf/202134205005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A.L., Sanjak M., Duffy K., Bravver E., Williams N., Nichols M., Brooks B.R. Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: Preliminary data for evidence-based guidelines. Arch. Phys. Med. Rehabil. 2010;91:268&#x2013;272. doi: 10.1016/j.apmr.2009.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2009.10.023</ArticleId><ArticleId IdType="pubmed">20159132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A.L., Hammond S., Holsten S., Bravver E., Brooks B.R. Power Wheelchair Use in Persons with Amyotrophic Lateral Sclerosis: Changes Over Time. Assist. Technol. 2015;27:238&#x2013;245. doi: 10.1080/10400435.2015.1040896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10400435.2015.1040896</ArticleId><ArticleId IdType="pubmed">26691564</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott M.A., Malvar H., Maassel L.L., Campbell J., Kulkarni H., Spiridonova I., Sophy N., Beavers J., Paradiso A., Needham C., et al. Eye-controlled, power wheelchair performs well for ALS patients. Muscle Nerve. 2019;60:513&#x2013;519. doi: 10.1002/mus.26655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26655</ArticleId><ArticleId IdType="pmc">PMC6851551</ArticleId><ArticleId IdType="pubmed">31397910</ArticleId></ArticleIdList></Reference><Reference><Citation>Manero A.C., McLinden S.L., Sparkman J., Oskarsson B. Evaluating surface EMG control of motorized wheelchairs for amyotrophic lateral sclerosis patients. J. Neuroeng. Rehabil. 2022;19:88. doi: 10.1186/s12984-022-01066-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12984-022-01066-8</ArticleId><ArticleId IdType="pmc">PMC9375912</ArticleId><ArticleId IdType="pubmed">35965311</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal H., Matthews A., Tea R., George K. LIDAR-based autonomous wheelchair; Proceedings of the 2017 IEEE Sensors Applications Symposium (SAS); Glassboro, NJ, USA. 13&#x2013;15 March 2017; pp. 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/SAS.2017.7894082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry K.S., Pelayo P., Anil D.G., George K. An SSVEP based brain computer interface system to control electric wheelchairs; Proceedings of the 2018 IEEE International Instrumentation and Measurement Technology Conference (I2MTC); Houston, TX, USA. 4&#x2013;17 May 2018; pp. 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/I2MTC.2018.8409632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanluk N., Visitsattapongse S., Juhong A., Pintavirooj C. Smart wheelchair based on eye tracking; Proceedings of the 2016 9th Biomedical Engineering International Conference (BMEiCON); Laung Prabang, Laos. 7&#x2013;9 December 2016; pp. 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/BMEiCON.2016.7859594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahmani M., Chowdhury M.E.H., Khandakar A., Rahman T., Al-Jayyousi K., Hefny A., Kiranyaz S. An Intelligent and Low-Cost Eye-Tracking System for Motorized Wheelchair Control. Sensors. 2020;20:3936. doi: 10.3390/s20143936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s20143936</ArticleId><ArticleId IdType="pmc">PMC7412002</ArticleId><ArticleId IdType="pubmed">32679779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Li Y., Long J., Yu T., Gu Z. An asynchronous wheelchair control by hybrid EEG-EOG brain-computer interface. Cogn. Neurodyn. 2014;8:399&#x2013;409. doi: 10.1007/s11571-014-9296-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11571-014-9296-y</ArticleId><ArticleId IdType="pmc">PMC4155067</ArticleId><ArticleId IdType="pubmed">25206933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bona S., Donvito G., Cozza F., Malberti I., Vaccari P., Lizio A., Greco L., Carraro E., Sansone V.A., Lunetta C. The development of an augmented reality device for the autonomous management of the electric bed and the electric wheelchair for patients with amyotrophic lateral sclerosis: A pilot study. Disabil. Rehabil. Assist. Technol. 2021;16:513&#x2013;519. doi: 10.1080/17483107.2019.1683237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17483107.2019.1683237</ArticleId><ArticleId IdType="pubmed">31686552</ArticleId></ArticleIdList></Reference><Reference><Citation>Londral A., Pinto A., Pinto S., Azevedo L., De Carvalho M. Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages. Muscle Nerve. 2015;52:933&#x2013;941. doi: 10.1002/mus.24659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24659</ArticleId><ArticleId IdType="pubmed">25808635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vansteensel M.J., Klein E., van Thiel G., Gaytant M., Simmons Z., Wolpaw J.R., Vaughan T.M. Towards clinical application of implantable brain-computer interfaces for people with late-stage ALS: Medical and ethical considerations. J. Neurol. 2023;270:1323&#x2013;1336. doi: 10.1007/s00415-022-11464-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11464-6</ArticleId><ArticleId IdType="pmc">PMC9971103</ArticleId><ArticleId IdType="pubmed">36450968</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett F., Kunz E., Fan C., Avansino D., Wilson G., Choi E.Y., Kamdar F., Hochberg L.R., Druckmann S., Shenoy K.V., et al. A high-performance speech neuroprosthesis. bioRxiv. 2023 doi: 10.1101/2023.01.21.524489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.21.524489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers E.W., Vaughan T.M., Wolpaw J.R. A brain-computer interface for long-term independent home use. Amyotroph. Lateral Scler. 2010;11:449&#x2013;455. doi: 10.3109/17482961003777470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003777470</ArticleId><ArticleId IdType="pubmed">20583947</ArticleId></ArticleIdList></Reference><Reference><Citation>Vansteensel M.J., Pels E.G.M., Bleichner M.G., Branco M.P., Denison T., Freudenburg Z.V., Gosselaar P., Leinders S., Ottens T.H., Van Den Boom M.A., et al. Fully Implanted Brain-Computer Interface in a Locked-In Patient with ALS. N. Engl. J. Med. 2016;375:2060&#x2013;2066. doi: 10.1056/NEJMoa1608085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1608085</ArticleId><ArticleId IdType="pmc">PMC5326682</ArticleId><ArticleId IdType="pubmed">27959736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolpaw J.R., Bedlack R.S., Reda D.J., Ringer R.J., Banks P.G., Vaughan T.M., Heckman S.M., McCane L.M., Carmack C.S., Winden S., et al. Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. Neurology. 2018;91:e258&#x2013;e267. doi: 10.1212/WNL.0000000000005812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005812</ArticleId><ArticleId IdType="pmc">PMC6059033</ArticleId><ArticleId IdType="pubmed">29950436</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hnlein P., Gdynia H.-J., Sperfeld A.-D., Lindner-Pfleghar B., Ludolph A.C., Prosiegel M., Riecker A. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat. Clin. Pract. Neurol. 2008;4:366&#x2013;374. doi: 10.1038/ncpneuro0853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneuro0853</ArticleId><ArticleId IdType="pubmed">18560390</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S.M., Elackattu A., Noordzij J.P., Walsh M.J., Langmore S.E. Palliative treatment of dysphonia and dysarthria. Otolaryngol. Clin. N. Am. 2009;42:107&#x2013;121. doi: 10.1016/j.otc.2008.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otc.2008.09.010</ArticleId><ArticleId IdType="pubmed">19134494</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattee G.L., Plowman E.K., Focht Garand K.L., Costello J., Brooks B.R., Berry J.D., Smith R.A., Atassi N., Chapin J.L., Yunusova Y., et al. Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59:531&#x2013;536. doi: 10.1002/mus.26408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26408</ArticleId><ArticleId IdType="pubmed">30620104</ArticleId></ArticleIdList></Reference><Reference><Citation>Collis J., Bloch S. Survey of UK speech and language therapists&#x2019; assessment and treatment practices for people with progressive dysarthria. Int. J. Lang. Commun. Disord. 2012;47:725&#x2013;737. doi: 10.1111/j.1460-6984.2012.00183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-6984.2012.00183.x</ArticleId><ArticleId IdType="pubmed">23121530</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S., Sieniawski M., Kollewe K., Rath K.J., Krampfl K., Zapf A., Dengler R., Petri S. Speech therapy and communication device: Impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2013;14:20&#x2013;25. doi: 10.3109/17482968.2012.692382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.692382</ArticleId><ArticleId IdType="pubmed">22871079</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Antona S., Caramenti M., Porro D., Castiglioni I., Cava C. Amyotrophic Lateral Sclerosis: A Diet Review. Foods. 2021;10:3128. doi: 10.3390/foods10123128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods10123128</ArticleId><ArticleId IdType="pmc">PMC8702143</ArticleId><ArticleId IdType="pubmed">34945679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T., Nakayama Y., Matsuda C., Haraguchi M., Bokuda K., Ishikawa-Takata K., Kawata A., Isozaki E. Prognostic significance of body weight variation after diagnosis in ALS: A single-centre prospective cohort study. J. Neurol. 2019;266:1412&#x2013;1420. doi: 10.1007/s00415-019-09276-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09276-2</ArticleId><ArticleId IdType="pubmed">30868220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Beard J.D., Umbach D.M., Bellocco R., Keller J., Peters T.L., Allen K.D., Ye W., Sandler D.P., Schmidt S., et al. Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am. J. Epidemiol. 2017;185:362&#x2013;371. doi: 10.1093/aje/kww140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww140</ArticleId><ArticleId IdType="pmc">PMC5860019</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C., Calvo A., Grassano M., Canosa A., Manera U., D&#x2019;Ovidio F., Bombaci A., Bersano E., Mazzini L., Mora G., et al. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort. J. Neurol. Neurosurg. Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Malerba S.A., Beghi E., Fini N., Fasano A., Zucchi E., De Pasqua S., Guidi C., Terlizzi E., Sette E., et al. Riluzole and other prognostic factors in ALS: A population-based registry study in Italy. J. Neurol. 2018;265:817&#x2013;827. doi: 10.1007/s00415-018-8778-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8778-y</ArticleId><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., van den Berg L.H., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm T., Maier A., Wicks P., Lang D., Linke P., M&#xfc;nch C., Steinfurth L., Meyer R., Meyer T. Severe loss of appetite in amyotrophic lateral sclerosis patients: Online self-assessment study. Interact. J. Med. Res. 2013;2:e8. doi: 10.2196/ijmr.2463.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/ijmr.2463</ArticleId><ArticleId IdType="pmc">PMC3632382</ArticleId><ArticleId IdType="pubmed">23608722</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos R., Bret&#xf3;n I., Cereda E., Desport J.C., Dziewas R., Genton L., Gomes F., J&#xe9;sus P., Leischker A., Muscaritoli M., et al. ESPEN guideline clinical nutrition in neurology. Clin. Nutr. 2018;37:354&#x2013;396. doi: 10.1016/j.clnu.2017.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2017.09.003</ArticleId><ArticleId IdType="pubmed">29274834</ArticleId></ArticleIdList></Reference><Reference><Citation>Padilla G.V., Grant M., Wong H., Hansen B.W., Hanson R.L., Bergstrom N., Kubo W.R. Subjective distresses of nasogastric tube feeding. J. Parenter. Enter. Nutr. 1979;3:53&#x2013;57. doi: 10.1177/014860717900300204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014860717900300204</ArticleId><ArticleId IdType="pubmed">110954</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C.A.R., Andriolo R.B., Bennett C., Lustosa S.A.S., Matos D., Waisberg D.R., Waisberg J. Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances. Cochrane Database Syst. Rev. 2015;2015:CD008096. doi: 10.1002/14651858.CD008096.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008096.pub4</ArticleId><ArticleId IdType="pmc">PMC6464742</ArticleId><ArticleId IdType="pubmed">25997528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond L., Ganguly P., Khamankar N., Mallet N., Bowen G., Green B., Mitchell C.S. A Comprehensive Examination of Percutaneous Endoscopic Gastrostomy and Its Association with Amyotrophic Lateral Sclerosis Patient Outcomes. Brain Sci. 2019;9:223. doi: 10.3390/brainsci9090223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci9090223</ArticleId><ArticleId IdType="pmc">PMC6770872</ArticleId><ArticleId IdType="pubmed">31487846</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C., Neuwirth C., Sommacal A., Andersen P.M., Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS ONE. 2017;12:e0177555. doi: 10.1371/journal.pone.0177555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177555</ArticleId><ArticleId IdType="pmc">PMC5441602</ArticleId><ArticleId IdType="pubmed">28542233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A., Fini N., Ferraro D., Ferri L., Vinceti M., Errals, Mandrioli J. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: A population-based registry study. Amyotroph. Lateral Scler. Front. Degener. 2017;18:233&#x2013;242. doi: 10.1080/21678421.2016.1270325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1270325</ArticleId><ArticleId IdType="pubmed">28076984</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., Ludolph A.C. Non-invasive ventilation in amyotrophic lateral sclerosis. Adv. Neurol. Disord. 2019;12:1756286419857040. doi: 10.1177/1756286419857040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286419857040</ArticleId><ArticleId IdType="pmc">PMC6589990</ArticleId><ArticleId IdType="pubmed">31258624</ArticleId></ArticleIdList></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: Current perspectives. Nat. Sci. Sleep. 2019;11:97&#x2013;111. doi: 10.2147/NSS.S183504.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSS.S183504</ArticleId><ArticleId IdType="pmc">PMC6701267</ArticleId><ArticleId IdType="pubmed">31496852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleopa K.A., Sherman M., Neal B., Romano G.J., Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J. Neurol. Sci. 1999;164:82&#x2013;88. doi: 10.1016/S0022-510X(99)00045-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00045-3</ArticleId><ArticleId IdType="pubmed">10385053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto A.C., Evangelista T., Carvalho M., Alves M.A., Sales Lu&#xed;s M.L. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: Survival rates in a controlled trial. J. Neurol. Sci. 1995;129:19&#x2013;26. doi: 10.1016/0022-510X(95)00052-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00052-4</ArticleId><ArticleId IdType="pubmed">7595610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J., Hsu J.Y., Hansen-Flaschen J., Elman L., Kawut S.M. Noninvasive Ventilation Use Is Associated with Better Survival in Amyotrophic Lateral Sclerosis. Ann. Am. Thorac. Soc. 2021;18:486&#x2013;494. doi: 10.1513/AnnalsATS.202002-169OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202002-169OC</ArticleId><ArticleId IdType="pmc">PMC7919153</ArticleId><ArticleId IdType="pubmed">32946280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke S.C., Bullock R.E., Williams T.L., Shaw P.J., Gibson G.J. Noninvasive ventilation in ALS: Indications and effect on quality of life. Neurology. 2003;61:171&#x2013;177. doi: 10.1212/01.wnl.0000076182.13137.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000076182.13137.38</ArticleId><ArticleId IdType="pubmed">12874394</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne E., Vrijsen B., Belge C., Testelmans D., Buyse B. Noninvasive ventilation in amyotrophic lateral sclerosis: Effects on sleep quality and quality of life. Acta Clin. Belg. 2016;71:389&#x2013;394. doi: 10.1080/17843286.2016.1173941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2016.1173941</ArticleId><ArticleId IdType="pubmed">27112318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi N., Atsuta N., Yokoi D., Nakamura R., Nakatochi M., Katsuno M., Izumi Y., Kanai K., Hattori N., Taniguchi A., et al. Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. J. Neurol. Neurosurg. Psychiatry. 2020;91:285&#x2013;290. doi: 10.1136/jnnp-2019-322213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322213</ArticleId><ArticleId IdType="pubmed">31937581</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittel S., Maier A., Kettemann D., Walter B., Koch B., Krause K., Norden J., M&#xfc;nch C., Meyer T. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. Eur. J. Neurol. 2021;28:1160&#x2013;1171. doi: 10.1111/ene.14647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14647</ArticleId><ArticleId IdType="pubmed">33210770</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Faull C., McDermott C.J., Nickol A.H., Palmer J., Talbot K. Tracheostomy in motor neurone disease. Pract. Neurol. 2019;19:467&#x2013;475. doi: 10.1136/practneurol-2018-002109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2018-002109</ArticleId><ArticleId IdType="pubmed">31273080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaub-Wittemer D., von Steinb&#xfc;chel N., Wasner M., Laier-Groeneveld G., Borasio G.D. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J. Pain Symptom Manag. 2003;26:890&#x2013;896. doi: 10.1016/S0885-3924(03)00323-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0885-3924(03)00323-3</ArticleId><ArticleId IdType="pubmed">14527757</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Wang Y., Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front. Pharm. 2022;13:1054006. doi: 10.3389/fphar.2022.1054006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1054006</ArticleId><ArticleId IdType="pmc">PMC9742490</ArticleId><ArticleId IdType="pubmed">36518658</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T., Funke A., M&#xfc;nch C., Kettemann D., Maier A., Walter B., Thomas A., Spittel S. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD) BMC Neurol. 2019;19:222. doi: 10.1186/s12883-019-1443-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-019-1443-y</ArticleId><ArticleId IdType="pmc">PMC6732193</ArticleId><ArticleId IdType="pubmed">31493784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacher P., B&#xe1;tkai S., Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharm. Rev. 2006;58:389&#x2013;462. doi: 10.1124/pr.58.3.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.58.3.2</ArticleId><ArticleId IdType="pmc">PMC2241751</ArticleId><ArticleId IdType="pubmed">16968947</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B., Broadley S., Bedlack R., Russo E., Sabet A. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: The EMERALD trial. BMJ Open. 2019;9:e029449. doi: 10.1136/bmjopen-2019-029449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-029449</ArticleId><ArticleId IdType="pmc">PMC6858175</ArticleId><ArticleId IdType="pubmed">31719072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C., Dakin R.S., Williamson J., Newton J., Steven M., Colville S., Stavrou M., Gregory J.M., Elliott E., Mehta A.R., et al. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): A multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12:e064173. doi: 10.1136/bmjopen-2022-064173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-064173</ArticleId><ArticleId IdType="pmc">PMC9263927</ArticleId><ArticleId IdType="pubmed">35798516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.-J., Raphael A.R., LaDow E.S., McGurk L., Weber R., Trojanowski J.Q., Lee V.M.-Y., Finkbeiner S., Gitler A.D., Bonini N.M. Therapeutic modulation of eIF2&#x3b1;-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat. Genet. 2014;46:152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T., McAvoy K., Russell K., Wen X., Pang Y., Morris B., Pasinelli P., Trotti D., Haeusler A. Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol. Med. 2019;11:e9423. doi: 10.15252/emmm.201809423.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809423</ArticleId><ArticleId IdType="pmc">PMC6365928</ArticleId><ArticleId IdType="pubmed">30617154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A., Gradus T., Altman T., Maimon R., Saraf Avraham N., Geva M., Hayden M., Perlson E. Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model. Cell Death Dis. 2019;10:210. doi: 10.1038/s41419-019-1451-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId><ArticleId IdType="pmc">PMC6397200</ArticleId><ArticleId IdType="pubmed">30824685</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C., Danel V., Devedjian J.C., Grolez G., Timmerman K., Laloux C., Petrault M., Gouel F., Jonneaux A., Dutheil M., et al. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid. Redox Signal. 2018;29:742&#x2013;748. doi: 10.1089/ars.2017.7493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7493</ArticleId><ArticleId IdType="pmc">PMC6067092</ArticleId><ArticleId IdType="pubmed">29287521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Wang Y., Zhang J., Shao Y., Li S., Wang Y., Cai H., Feng Y., Le W. Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis. Sci. Rep. 2018;8:1668. doi: 10.1038/s41598-018-19923-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19923-9</ArticleId><ArticleId IdType="pmc">PMC5786035</ArticleId><ArticleId IdType="pubmed">29374221</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E.J. A Novel Supplement Attenuates Oxidative Stress-Induced TDP-43-Related Pathogenesis in TDP-43-Expressed Cells. Evid.-Based Complement. Altern. Med. 2021;2021:e6773260. doi: 10.1155/2021/6773260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6773260</ArticleId><ArticleId IdType="pmc">PMC8490039</ArticleId><ArticleId IdType="pubmed">34616479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J., Rowe D.B., Kiernan M.C., Vucic S., Mathers S., van Eijk R.P.A., Nath A., Garcia Montojo M., Norato G., Santamaria U.A., et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: The Lighthouse trial. Amyotroph. Lateral Scler. Front. Degener. 2019;20:595&#x2013;604. doi: 10.1080/21678421.2019.1632899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632899</ArticleId><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Maragakis N., Bedlack R.S., Goyal N., Meyer J.A., Genge A., Bodkin C., Maiser S., Staff N., Zinman L., et al. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegener. Dis. Manag. 2021;11:431&#x2013;443. doi: 10.2217/nmt-2021-0042.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2021-0042</ArticleId><ArticleId IdType="pubmed">34816762</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang H., Ying Z., Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem. Biophys. Res. Commun. 2020;526:231&#x2013;238. doi: 10.1016/j.bbrc.2020.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.051</ArticleId><ArticleId IdType="pubmed">32204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hern&#xe1;ndez M., Mar&#xed;n S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Bradley W.G., Chaverri D., Hern&#xe1;ndez-Barral M., Mascias J., Gamez J., Gargiulo-Monachelli G.M., Moussy A., Mansfield C.D., Hermine O., et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Adv. Neurol. Disord. 2021;14:17562864211030364. doi: 10.1177/17562864211030365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864211030365</ArticleId><ArticleId IdType="pmc">PMC8388186</ArticleId><ArticleId IdType="pubmed">34457038</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova N., Georgievska B., Eriksson H., Poewe W., Wenning G.K. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox. Res. 2012;21:393&#x2013;404. doi: 10.1007/s12640-011-9294-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-011-9294-3</ArticleId><ArticleId IdType="pubmed">22161470</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong L., McCoy M., Komuro H., West X.Z., Yakubenko V., Gao D., Dudiki T., Milo A., Chen J., Podrez E.A., et al. Inflammation-dependent oxidative stress metabolites as a hallmark of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2022;178:125&#x2013;133. doi: 10.1016/j.freeradbiomed.2021.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.11.031</ArticleId><ArticleId IdType="pmc">PMC8744315</ArticleId><ArticleId IdType="pubmed">34871763</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K., Nassif M., Valenzuela V., Rojas F., Matus S., Mercado G., Court F.A., van Zundert B., Hetz C. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308&#x2013;1320. doi: 10.4161/auto.25188.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.25188</ArticleId><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Guo Y., Wang X., Yu X., Duan W., Hong K., Wang J., Han H., Li C. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015;298:12&#x2013;25. doi: 10.1016/j.neuroscience.2015.03.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.061</ArticleId><ArticleId IdType="pubmed">25841320</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Andrews J.A., Genge A., Jackson C., Lechtzin N., Miller T.M., Cockroft B.M., Meng L., Wei J., Wolff A.A., et al. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial of Reldesemtiv in Patients with ALS. Amyotroph. Lateral Scler. Front. Degener. 2021;22:287&#x2013;299. doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R., Izumi Y., Fujita K., Miyamoto R., Nodera H., Sato Y., Sakaguchi S., Nokihara H., Kanai K., Tsunemi T., et al. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2022;79:575&#x2013;583. doi: 10.1001/jamaneurol.2022.0901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId><ArticleId IdType="pmc">PMC9086935</ArticleId><ArticleId IdType="pubmed">35532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musar&#xf2; A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007;1185:256&#x2013;265. doi: 10.1016/j.brainres.2007.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.034</ArticleId><ArticleId IdType="pmc">PMC2265207</ArticleId><ArticleId IdType="pubmed">17963733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Treleaven C.M., Fidler J.A., Hester M., Haidet A., Handy C., Rao M., Eagle A., Matthews J.C., Taksir T.V., et al. AAV4-mediated Expression of IGF-1 and VEGF within Cellular Components of the Ventricular System Improves Survival Outcome in Familial ALS Mice. Mol. Ther. 2010;18:2075&#x2013;2084. doi: 10.1038/mt.2010.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.206</ArticleId><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H., Hu H., Duan W., Liu Y., Tan G., Li Z., Liu Y., Deng B., Song X., Wang W., et al. Intramuscular Delivery of scAAV9-hIGF1 Prolongs Survival in the hSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. Mol. Neurobiol. 2018;55:682&#x2013;695. doi: 10.1007/s12035-016-0335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0335-z</ArticleId><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770&#x2013;1775. doi: 10.1212/01.wnl.0000335970.78664.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000335970.78664.36</ArticleId><ArticleId IdType="pmc">PMC2617770</ArticleId><ArticleId IdType="pubmed">19029516</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson A.P., Zhang J.Z., Titus H.E., Karl M., Merzliakov M., Dorfman A.R., Karlik S., Stewart M.G., Watt R.K., Facer B.D., et al. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci. Rep. 2020;10:1936. doi: 10.1038/s41598-020-58709-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58709-w</ArticleId><ArticleId IdType="pmc">PMC7010780</ArticleId><ArticleId IdType="pubmed">32041968</ArticleId></ArticleIdList></Reference><Reference><Citation>Aartsma-Rus A. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid. 2017;27:67&#x2013;69. doi: 10.1089/nat.2017.0665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2017.0665</ArticleId><ArticleId IdType="pubmed">28346110</ArticleId></ArticleIdList></Reference><Reference><Citation>Aartsma-Rus A., Krieg A.M. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017;27:1&#x2013;3. doi: 10.1089/nat.2016.0657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/nat.2016.0657</ArticleId><ArticleId IdType="pmc">PMC5312460</ArticleId><ArticleId IdType="pubmed">27929755</ArticleId></ArticleIdList></Reference><Reference><Citation>Boros B.D., Schoch K.M., Kreple C.J., Miller T.M. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics. 2022;19:1145&#x2013;1158. doi: 10.1007/s13311-022-01247-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01247-2</ArticleId><ArticleId IdType="pmc">PMC9587169</ArticleId><ArticleId IdType="pubmed">35653060</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov V.A., Lyashchenko A.K., Blanco-Redondo B., Jafar-Nejad P., Shneider N.A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 2022;28:104&#x2013;116. doi: 10.1038/s41591-021-01615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Lin S., Staats K.A., Li Y., Chang W.-H., Hung S.-T., Hendricks E., Linares G.R., Wang Y., Son E.Y., et al. Haploinsufficiency Leads to Neurodegeneration in C9ORF72 ALS/FTD Human Induced Motor Neurons. Nat. Med. 2018;24:313&#x2013;325. doi: 10.1038/nm.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4490</ArticleId><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>McEachin Z.T., Parameswaren J., Raj N., Bassell G.J., Jiang J. RNA-mediated toxicity in C9orf72 ALS and FTD. Neurobiol. Dis. 2020;145:105055. doi: 10.1016/j.nbd.2020.105055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105055</ArticleId><ArticleId IdType="pmc">PMC7572710</ArticleId><ArticleId IdType="pubmed">32829028</ArticleId></ArticleIdList></Reference><Reference><Citation>Vel&#xe1;zquez-P&#xe9;rez L.C., Rodr&#xed;guez-Labrada R., Fernandez-Ruiz J. Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches. Front. Neurol. 2017;8:472. doi: 10.3389/fneur.2017.00472.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00472</ArticleId><ArticleId IdType="pmc">PMC5601978</ArticleId><ArticleId IdType="pubmed">28955296</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene therapy for ALS: A review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; B., Lehmann M., Beaudin M., Nordstr&#xf6;m U., Saikali S., Julien J.-P., Gilthorpe J.D., Marklund S.L., Cashman N.R., Andersen P.M., et al. Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis. Sci. Rep. 2018;8:14223. doi: 10.1038/s41598-018-31773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31773-z</ArticleId><ArticleId IdType="pmc">PMC6155098</ArticleId><ArticleId IdType="pubmed">30242181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zancanella V., van Rooijen K., van Vliet R., Pereira I., de Ruiter A., Shtefaniuk V., Kieper S., Wartel M., Dobrynin G., Kova&#x10d;evi&#x107; J., et al. AAV-miQURE&#xae;-mediated targeting of hexanucleotide repeat expansion-containing transcripts in ALS C9orf72 mouse models. Hum. Gene Ther. 2022;33:A72&#x2013;A73.</Citation></Reference><Reference><Citation>Redman M., King A., Watson C., King D. What is CRISPR/Cas9? Arch. Dis. Child. Educ. Pract. 2016;101:213&#x2013;215. doi: 10.1136/archdischild-2016-310459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2016-310459</ArticleId><ArticleId IdType="pmc">PMC4975809</ArticleId><ArticleId IdType="pubmed">27059283</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijboom K.E., Abdallah A., Fordham N.P., Nagase H., Rodriguez T., Kraus C., Gendron T.F., Krishnan G., Esanov R., Andrade N.S., et al. CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro. Nat. Commun. 2022;13:6286. doi: 10.1038/s41467-022-33332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33332-7</ArticleId><ArticleId IdType="pmc">PMC9587249</ArticleId><ArticleId IdType="pubmed">36271076</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Zhai H., Shi Y., Liu G., Lowry J., Liu B., Ryan &#xc9;.B., Yan J., Yang Y., Zhang N., et al. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS. Commun. Biol. 2021;4:396. doi: 10.1038/s42003-021-01942-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01942-4</ArticleId><ArticleId IdType="pmc">PMC7994668</ArticleId><ArticleId IdType="pubmed">33767386</ArticleId></ArticleIdList></Reference><Reference><Citation>Deneault E., Chaineau M., Nicouleau M., Castellanos Montiel M.J., Franco Flores A.K., Haghi G., Chen C.X.-Q., Abdian N., Shlaifer I., Beitel L.K., et al. A streamlined CRISPR workflow to introduce mutations and generate isogenic iPSCs for modeling amyotrophic lateral sclerosis. Methods. 2022;203:297&#x2013;310. doi: 10.1016/j.ymeth.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2021.09.002</ArticleId><ArticleId IdType="pubmed">34500068</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel S., Herdewyn S., Fazal R., De Decker M., Moisse M., Robberecht W., Van Den Bosch L., Van Damme P. Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Mol. Neurodegener. 2018;13:55. doi: 10.1186/s13024-018-0288-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0288-y</ArticleId><ArticleId IdType="pmc">PMC6192075</ArticleId><ArticleId IdType="pubmed">30326935</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymick J.C., Yang Y., Andersen P.M., Vonsattel J.P., Greenway M., Momeni P., Elder J., Chi&#xf2; A., Restagno G., Robberecht W., et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis&#x2013;frontotemporal dementia phenotypes. J. Neurol. Neurosurg. Psychiatry. 2007;78:754&#x2013;756. doi: 10.1136/jnnp.2006.109553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.109553</ArticleId><ArticleId IdType="pmc">PMC2117704</ArticleId><ArticleId IdType="pubmed">17371905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon A., Fujioka S., Rutherford N.J., Ferman T.J., Broderick D.F., Boylan K.B., Graff-Radford N.R., Uitti R.J., Rademakers R., Wszolek Z.K., et al. Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. Neurology. 2013;80:1771&#x2013;1777. doi: 10.1212/WNL.0b013e3182919059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182919059</ArticleId><ArticleId IdType="pmc">PMC3719429</ArticleId><ArticleId IdType="pubmed">23596077</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier M., Welt T., Wirth F., Montrasio F., Preisig D., McAfoose J., Vieira F.G., Kulic L., Sp&#xe4;ni C., Stehle T., et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci. Transl. Med. 2018;10:eaah3924. doi: 10.1126/scitranslmed.aah3924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah3924</ArticleId><ArticleId IdType="pubmed">30518612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi F., De Marchi F., Mazzini L., Bendotti C. Cell therapy in ALS: An update on preclinical and clinical studies. Brain Res. Bull. 2023;194:64&#x2013;81. doi: 10.1016/j.brainresbull.2023.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2023.01.008</ArticleId><ArticleId IdType="pubmed">36690163</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., Lindborg S.R., Goyal N.A., Miller R.G., Burford M.J., Berry J.D., Nicholson K.A., Mozaffar T., Katz J.S., Jenkins L.J., et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65:291&#x2013;302. doi: 10.1002/mus.27472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27472</ArticleId><ArticleId IdType="pmc">PMC9305113</ArticleId><ArticleId IdType="pubmed">34890069</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K.-W., Noh M.-Y., Kwon M.-S., Kim H.Y., Oh S., Park J., Kim H.-J., Ki C.-S., Kim S.H. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis. Ann. Neurol. 2018;84:361&#x2013;373. doi: 10.1002/ana.25302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25302</ArticleId><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas A., Chen J., Kuang L., Barnett K.R., Kasarskis E.J., Gal J., Zhu H. Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS. Hum. Mol. Genet. 2020;29:2684&#x2013;2697. doi: 10.1093/hmg/ddaa159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa159</ArticleId><ArticleId IdType="pmc">PMC7530527</ArticleId><ArticleId IdType="pubmed">32691043</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffert L.-N., Carter W.G. Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review. Brain Sci. 2020;10:232. doi: 10.3390/brainsci10040232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10040232</ArticleId><ArticleId IdType="pmc">PMC7226274</ArticleId><ArticleId IdType="pubmed">32290481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoads S.N., Monahan Z.T., Yee D.S., Shewmaker F.P. The Role of Post-Translational Modifications on Prion-Like Aggregation and Liquid-Phase Separation of FUS. Int. J. Mol. Sci. 2018;19:886. doi: 10.3390/ijms19030886.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030886</ArticleId><ArticleId IdType="pmc">PMC5877747</ArticleId><ArticleId IdType="pubmed">29547565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S., Esposito S., Masala A., Sini P., Nieddu G., Galioto M., Fais M., Iaccarino C., Cestra G., Crosio C. HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo. Cell Death Dis. 2020;11:369. doi: 10.1038/s41419-020-2580-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2580-3</ArticleId><ArticleId IdType="pmc">PMC7224392</ArticleId><ArticleId IdType="pubmed">32409664</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks C.J., Andersen J.L. Mechanisms of SOD1 regulation by post-translational modifications. Redox Biol. 2019;26:101270. doi: 10.1016/j.redox.2019.101270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101270</ArticleId><ArticleId IdType="pmc">PMC6658992</ArticleId><ArticleId IdType="pubmed">31344643</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Genoud S., Roudeau S., Rookyard A., Abdeen A., Cottam V., Hare D.J., White M., Altvater J., Fifita J.A., et al. Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022;145:3108&#x2013;3130. doi: 10.1093/brain/awac165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac165</ArticleId><ArticleId IdType="pmc">PMC9473357</ArticleId><ArticleId IdType="pubmed">35512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Barski A., Cuddapah S., Cui K., Roh T.-Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-Resolution Profiling of Histone Methylations in the Human Genome. Cell. 2007;129:823&#x2013;837. doi: 10.1016/j.cell.2007.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.05.009</ArticleId><ArticleId IdType="pubmed">17512414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Zang C., Rosenfeld J.A., Schones D.E., Barski A., Cuddapah S., Cui K., Roh T.-Y., Peng W., Zhang M.Q., et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 2008;40:897&#x2013;903. doi: 10.1038/ng.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.154</ArticleId><ArticleId IdType="pmc">PMC2769248</ArticleId><ArticleId IdType="pubmed">18552846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138:1019&#x2013;1031. doi: 10.1016/j.cell.2009.06.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.06.049</ArticleId><ArticleId IdType="pmc">PMC2750862</ArticleId><ArticleId IdType="pubmed">19698979</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng C.-S., Wu B.-H., Yen M.-R., Chen P.-Y. MethGET: Web-based bioinformatics software for correlating genome-wide DNA methylation and gene expression. BMC Genom. 2020;21:375. doi: 10.1186/s12864-020-6722-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-020-6722-x</ArticleId><ArticleId IdType="pmc">PMC7257144</ArticleId><ArticleId IdType="pubmed">32471342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt C.R., Ramnarain D., Horikoshi N., Iyengar P., Pandita R.K., Shay J.W., Pandita T.K. Histone Modifications and DNA Double-Strand Break Repair after Exposure to Ionizing Radiations. Radiat. Res. 2013;179:383&#x2013;392. doi: 10.1667/RR3308.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1667/RR3308.2</ArticleId><ArticleId IdType="pmc">PMC4133051</ArticleId><ArticleId IdType="pubmed">23373901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett S.A., Tanaz R., Cobos S.N., Torrente M.P. Epigenetics in amyotrophic lateral sclerosis: A role for histone post-translational modifications in neurodegenerative disease. Transl. Res. 2019;204:19&#x2013;30. doi: 10.1016/j.trsl.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2018.10.002</ArticleId><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobos S.N., Bennett S.A., Torrente M.P. The impact of histone post-translational modifications in neurodegenerative diseases. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2019;1865:1982&#x2013;1991. doi: 10.1016/j.bbadis.2018.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.10.019</ArticleId><ArticleId IdType="pmc">PMC6475498</ArticleId><ArticleId IdType="pubmed">30352259</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobos S.N., Torrente M.P. Epidrugs in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia: Contextualizing a Role for Histone Kinase Inhibition in Neurodegenerative Disease. ACS Pharmacol. Transl. Sci. 2022;5:134&#x2013;137. doi: 10.1021/acsptsci.1c00265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.1c00265</ArticleId><ArticleId IdType="pmc">PMC8844958</ArticleId><ArticleId IdType="pubmed">35187420</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingl Y.E., Pakravan D., Bosch L.V.D. Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. Br. J. Pharmacol. 2021;178:1353&#x2013;1372. doi: 10.1111/bph.15217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15217</ArticleId><ArticleId IdType="pmc">PMC9327724</ArticleId><ArticleId IdType="pubmed">32726472</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordov&#xe1;s L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Burg T., Rossaert E., Moisse M., Van Damme P., Van Den Bosch L. Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:11224. doi: 10.3390/ijms222011224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011224</ArticleId><ArticleId IdType="pmc">PMC8541517</ArticleId><ArticleId IdType="pubmed">34681883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejido C., Pakravan D., Bosch L.V.D. Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS. Front. Mol. Neurosci. 2021;14:154. doi: 10.3389/fnmol.2021.686995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.686995</ArticleId><ArticleId IdType="pmc">PMC8380926</ArticleId><ArticleId IdType="pubmed">34434087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazal R., Boeynaems S., Swijsen A., De Decker M., Fumagalli L., Moisse M., Vanneste J., Guo W., Boon R., Vercruysse T., et al. HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J. 2021;40:e106177. doi: 10.15252/embj.2020106177.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106177</ArticleId><ArticleId IdType="pmc">PMC8013789</ArticleId><ArticleId IdType="pubmed">33694180</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutillier A.-L., Tzeplaeff L., Dupuis L. The dark side of HDAC inhibition in ALS. EBioMedicine. 2019;41:38&#x2013;39. doi: 10.1016/j.ebiom.2019.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.02.039</ArticleId><ArticleId IdType="pmc">PMC6443023</ArticleId><ArticleId IdType="pubmed">30803935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahana T.G., Zhang K. Mitogen-Activated Protein Kinase Pathway in Amyotrophic Lateral Sclerosis. Biomedicines. 2021;9:969. doi: 10.3390/biomedicines9080969.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080969</ArticleId><ArticleId IdType="pmc">PMC8394856</ArticleId><ArticleId IdType="pubmed">34440173</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br. J. Pharmacol. 2021;178:1298&#x2013;1315. doi: 10.1111/bph.15148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P., Weber M., Camu W., Friede T., Hilgers R., Leha A., Neuwirth C., G&#xfc;nther R., Benatar M., Kuzma-Kozakiewicz M., et al. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:293. doi: 10.3389/fneur.2019.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00293</ArticleId><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J.C., Tatenhorst L., Roser A.-E., Saal K.-A., T&#xf6;nges L., Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharm. 2018;189:1&#x2013;21. doi: 10.1016/j.pharmthera.2018.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.03.008</ArticleId><ArticleId IdType="pubmed">29621594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop P.J., Zwamborn R.A.J., Hannon E., Shireby G.L., Nabais M.F., Walker E.M., van Rheenen W., van Vugt J.J.F.A., Dekker A.M., Westeneng H.-J., et al. Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med. 2022;14:eabj0264. doi: 10.1126/scitranslmed.abj0264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj0264</ArticleId><ArticleId IdType="pmc">PMC10040186</ArticleId><ArticleId IdType="pubmed">35196023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chestnut B.A., Chang Q., Price A., Lesuisse C., Wong M., Martin L.J. Epigenetic regulation of motor neuron cell death through DNA methylation. J. Neurosci. 2011;31:16619&#x2013;16636. doi: 10.1523/JNEUROSCI.1639-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1639-11.2011</ArticleId><ArticleId IdType="pmc">PMC3238138</ArticleId><ArticleId IdType="pubmed">22090490</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Wong M. Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: A new target of disease mechanisms. Neurotherapeutics. 2013;10:722&#x2013;733. doi: 10.1007/s13311-013-0205-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0205-6</ArticleId><ArticleId IdType="pmc">PMC3805862</ArticleId><ArticleId IdType="pubmed">23900692</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Fumagalli L., Bosch L.V.D., Guo W., Fumagalli L., Bosch L.V.D. Targeting Axonal Transport: A New Therapeutic Avenue for ALS. IntechOpen; London, UK: 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/intechopen.91963</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanneste J., Van Den Bosch L. The Role of Nucleocytoplasmic Transport Defects in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:12175. doi: 10.3390/ijms222212175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212175</ArticleId><ArticleId IdType="pmc">PMC8620263</ArticleId><ArticleId IdType="pubmed">34830069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9ORF72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.-C., Zhang Y., Umoh M.E., Vaughan S.W., Lorenzini I., Liu F., Sayegh M., Donlin-Asp P.G., Chen Y.H., Duong D.M., et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., Sun S., Herdy J.R., Bieri G., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Fare C.M., Shorter J. Therapeutic dissolution of aberrant phases by nuclear-import receptors. Trends Cell Biol. 2019;29:308&#x2013;322. doi: 10.1016/j.tcb.2018.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2018.12.004</ArticleId><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A., Atkin J.D. DNA Damage, Defective DNA Repair, and Neurodegeneration in Amyotrophic Lateral Sclerosis. Front. Aging Neurosci. 2022;14:786420. doi: 10.3389/fnagi.2022.786420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.786420</ArticleId><ArticleId IdType="pmc">PMC9093740</ArticleId><ArticleId IdType="pubmed">35572138</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L., Mojsilovic-Petrovic J., Van Deerlin V.M., Shorter J., Kalb R.G., Lee V.M., Trojanowski J.Q., Lee E.B., Bonini N.M. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2018;6:84. doi: 10.1186/s40478-018-0586-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0586-1</ArticleId><ArticleId IdType="pmc">PMC6114235</ArticleId><ArticleId IdType="pubmed">30157956</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D.G., Shorter J., Wobst H.J. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorganic Med. Chem. Lett. 2020;30:126942. doi: 10.1016/j.bmcl.2019.126942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2019.126942</ArticleId><ArticleId IdType="pubmed">31926785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan Y., Fang Q., Zhang N., Kumar G., Zhang J., Song L.-J., Yu J., Zhao L., Zhang H.-T., et al. The Rho kinase inhibitor fasudil attenuates A&#x3b2;1&#x2013;42-induced apoptosis via the ASK1/JNK signal pathway in primary cultures of hippocampal neurons. Metab. Brain Dis. 2019;34:1787&#x2013;1801. doi: 10.1007/s11011-019-00487-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-019-00487-0</ArticleId><ArticleId IdType="pubmed">31482248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A., Pollastro F., Bramanti P., Mazzon E. Cannabidiol exerts protective effects in an in vitro model of Parkinson&#x2019;s disease activating AKT/mTOR pathway. Fitoterapia. 2020;143:104553. doi: 10.1016/j.fitote.2020.104553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2020.104553</ArticleId><ArticleId IdType="pubmed">32184097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Lopes D.H.J., Du Z., Pang E.S., Shanmugam A., Lomakin A., Talbiersky P., Tennstaedt A., McDaniel K., Bakshi R., et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J. Am. Chem. Soc. 2011;133:16958&#x2013;16969. doi: 10.1021/ja206279b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja206279b</ArticleId><ArticleId IdType="pmc">PMC3210512</ArticleId><ArticleId IdType="pubmed">21916458</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R., Meng H., Wongkongkathep P., Corrales C.I., Sepanj N., Atlasi R.S., Kl&#xe4;rner F.-G., Schrader T., Spencer M.J., Loo J.A., et al. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. J. Biol. Chem. 2019;294:3501&#x2013;3513. doi: 10.1074/jbc.RA118.005940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005940</ArticleId><ArticleId IdType="pmc">PMC6416427</ArticleId><ArticleId IdType="pubmed">30602569</ArticleId></ArticleIdList></Reference><Reference><Citation>Samanta N., Ruiz-Blanco Y.B., Fetahaj Z., Gnutt D., Lantz C., Loo J.A., Sanchez-Garcia E., Ebbinghaus S. Superoxide Dismutase 1 Folding Stability as a Target for Molecular Tweezers in SOD1-Related Amyotrophic Lateral Sclerosis. ChemBioChem. 2022;23:e202200396. doi: 10.1002/cbic.202200396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202200396</ArticleId><ArticleId IdType="pmc">PMC9828543</ArticleId><ArticleId IdType="pubmed">36083789</ArticleId></ArticleIdList></Reference><Reference><Citation>Di J., Siddique I., Li Z., Malki G., Hornung S., Dutta S., Hurst I., Ishaaya E., Wang A., Tu S., et al. The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alzheimer&#x2019;s Res. Ther. 2021;13:6. doi: 10.1186/s13195-020-00743-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00743-x</ArticleId><ArticleId IdType="pmc">PMC7784007</ArticleId><ArticleId IdType="pubmed">33397489</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal N.A., Berry J.D., Windebank A., Staff N.P., Maragakis N.J., van den Berg L.H., Genge A., Miller R., Baloh R.H., Kern R., et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62:156&#x2013;166. doi: 10.1002/mus.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Feldman E.L. Clinical Trials of Therapies for Amyotrophic Lateral Sclerosis: One Size Does Not Fit All. JAMA Neurol. 2015;72:743&#x2013;744. doi: 10.1001/jamaneurol.2014.4275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.4275</ArticleId><ArticleId IdType="pmc">PMC5499507</ArticleId><ArticleId IdType="pubmed">25961436</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney N.T., Spina S., Miller B.L. Frontotemporal Dementia. Neurol. Clin. 2017;35:339&#x2013;374. doi: 10.1016/j.ncl.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2017.01.008</ArticleId><ArticleId IdType="pmc">PMC5472209</ArticleId><ArticleId IdType="pubmed">28410663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaque A., Mah D., Seres P., Luk C., Eurich D., Johnston W., Yang Y.-H., Kalra S. Evaluating the cerebral correlates of survival in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2018;5:1350&#x2013;1361. doi: 10.1002/acn3.655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.655</ArticleId><ArticleId IdType="pmc">PMC6243384</ArticleId><ArticleId IdType="pubmed">30480029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Moglia C., Mazzini L., Mora G., PARALS Study Group Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J. Neurol. Neurosurg. Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q.-Q., Chen Y., Chen X., Cao B., Ou R., Zhang L., Hou Y., Shang H. Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry. Brain Res. Bull. 2018;142:403&#x2013;408. doi: 10.1016/j.brainresbull.2018.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.09.005</ArticleId><ArticleId IdType="pubmed">30232045</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.-J., Debray T.P.A., Visser A.E., van Eijk R.P.A., Rooney J.P.K., Calvo A., Martin S., McDermott C.J., Thompson A.G., Pinto S., et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J., Hansen-Flaschen J., Wileyto E.P., Schwab R.J., Elman L., Kawut S.M. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur. Respir. J. 2019;53:1802237. doi: 10.1183/13993003.02237-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02237-2018</ArticleId><ArticleId IdType="pmc">PMC6684229</ArticleId><ArticleId IdType="pubmed">30728207</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K., Anoja N., Breiner A., Chum M., Dionne A., Dupr&#xe9; N., Fiander A., Fok D., Ghavanini A., Gosselin S., et al. Genetic testing for amyotrophic lateral sclerosis in Canada&#x2014;An assessment of current practices. Amyotroph. Lateral Scler. Front. Degener. 2022;23:305&#x2013;312. doi: 10.1080/21678421.2021.1980890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1980890</ArticleId><ArticleId IdType="pubmed">34569363</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K., Oh K.-W., Nordin A., Panthi S., Kim S.H., Nordin F., Freischmidt A., Ludolph A.C., Ki C.S., Forsberg K., et al. De novo mutations in SOD1 are a cause of ALS. J. Neurol. Neurosurg. Psychiatry. 2022;93:201&#x2013;206. doi: 10.1136/jnnp-2021-327520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327520</ArticleId><ArticleId IdType="pmc">PMC8784989</ArticleId><ArticleId IdType="pubmed">34518333</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassano M., Calvo A., Moglia C., Sbaiz L., Brunetti M., Barberis M., Casale F., Manera U., Vasta R., Canosa A., et al. Systematic evaluation of genetic mutations in ALS: A population-based study. J. Neurol. Neurosurg. Psychiatry. 2022;93:1190&#x2013;1193. doi: 10.1136/jnnp-2022-328931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-328931</ArticleId><ArticleId IdType="pmc">PMC9606529</ArticleId><ArticleId IdType="pubmed">35896380</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Bucelli R.C., Andrews J.A., Otto M., Farahany N.A., Harrington E.A., Chen W., Mitchell A.A., et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: The ATLAS Study. Neurotherapeutics. 2022;19:1248&#x2013;1258. doi: 10.1007/s13311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01237-4</ArticleId><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., McHutchison C., Postuma R.B., Boeve B.F., Petersen R., Ross C.A., Rosen H., Arias J.J., Fradette S., et al. Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27&#x2013;44. doi: 10.1093/brain/awab404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab404</ArticleId><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidovic M., M&#xfc;schen L.H., Brakemeier S., Machetanz G., Naumann M., Castro-Gomez S. Current State and Future Directions in the Diagnosis of Amyotrophic Lateral Sclerosis. Cells. 2023;12:736. doi: 10.3390/cells12050736.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050736</ArticleId><ArticleId IdType="pmc">PMC10000757</ArticleId><ArticleId IdType="pubmed">36899872</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturmey E., Malaspina A. Blood biomarkers in ALS: Challenges, applications and novel frontiers. Acta Neurol. Scand. 2022;146:375&#x2013;388. doi: 10.1111/ane.13698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13698</ArticleId><ArticleId IdType="pmc">PMC9828487</ArticleId><ArticleId IdType="pubmed">36156207</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L., Blennow K., Calabresi P., Di Filippo M., Parnetti L., Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 2019;90:870&#x2013;881. doi: 10.1136/jnnp-2018-320106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J., Norgren N., Dobson R., Topping J., Nissim A., Malaspina A., Bestwick J.P., Monsch A.U., Regeniter A., Lindberg R.L., et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE. 2013;8:e75091. doi: 10.1371/journal.pone.0075091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.-H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Fratta P., Sidle K., Fish M., et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Gray E., Verber N., Bobeva Y., Lombardi V., Shepheard S.R., Yildiz O., Feneberg E., Farrimond L., Dharmadasa T., et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029. doi: 10.1093/braincomms/fcac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V., Mastrangelo A., Zenesini C., Masullo M., Quadalti C., Avoni P., Polischi B., Cherici A., Capellari S., Salvi F., et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front. Aging Neurosci. 2021;13:753242. doi: 10.3389/fnagi.2021.753242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.753242</ArticleId><ArticleId IdType="pmc">PMC8569186</ArticleId><ArticleId IdType="pubmed">34744694</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Lombardi V., Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I., Yacovzada N.S., Yanowski E., Coenen-Stass A., Grosskreutz J., Lu C.-H., Greensmith L., Malaspina A., Fratta P., Hornstein E. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. 2021;24:1534&#x2013;1541. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Li S., Chen S., Sun X., Yang F., Wang H., Li M., Cui F., Huang X. TDP-43 and Phosphorylated TDP-43 Levels in Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front. Neurol. 2021;12:663637. doi: 10.3389/fneur.2021.663637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.663637</ArticleId><ArticleId IdType="pmc">PMC8236522</ArticleId><ArticleId IdType="pubmed">34194383</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293&#x2013;1314. doi: 10.1093/brain/awr074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean R.K., McKay F.C., Cretney E., Bye C.R., Perera N.D., Tomas D., Weston R.A., Scheller K.J., Djouma E., Menon P., et al. Association of Regulatory T-Cell Expansion with Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Karnaros V., Benyamin B., Schultz D.W., Dubowsky M., Wuu J., Chataway T., Malaspina A., Benatar M., Rogers M.-L. Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. Eur. J. Neurol. 2022;29:990&#x2013;999. doi: 10.1111/ene.15237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15237</ArticleId><ArticleId IdType="pmc">PMC8901536</ArticleId><ArticleId IdType="pubmed">34967083</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Wuu J., Cardoso M., Wiklendt L., Dinning P.G., Chataway T., Schultz D., Benatar M., Rogers M.-L. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ami D., Duse A., Mereghetti P., Cozza F., Ambrosio F., Ponzini E., Grandori R., Lunetta C., Tavazzi S., Pezzoli F., et al. Tear-Based Vibrational Spectroscopy Applied to Amyotrophic Lateral Sclerosis. Anal. Chem. 2021;93:16995&#x2013;17002. doi: 10.1021/acs.analchem.1c02546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c02546</ArticleId><ArticleId IdType="pmc">PMC8717331</ArticleId><ArticleId IdType="pubmed">34905686</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chi&#xf2; A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>